Increased individual ownership through share exchange from Maas Biolab, LLC
One of NeuroVive’s largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas Biolab reducing its ownership of NeuroVive from 15.24% to 13.94%, and individual shareholders, including members of NeuroVive’s management, Board of Directors and co-founders, increasing their personal holdings in NeuroVive.
“With this share exchange, Maas Biolab is continuing the strategy set in previous years of increasing the proportion of individual shareholdings in NeuroVive. Similar share swaps, of differing scales, have been executed on four previous occasions in the period 2009-2012,” commented NeuroVive’s Chairman, Greg Batcheller.
The transfer of shares from Maas Biolab, LLC to individual shareholders is being conducted off the market and is scheduled for completion by April 8th 2014. Increases to insider holdings will be reported in the customary manner. Maas Biolab LLC’s total transfer (reduced holdings) will be recognised as a decrease in the related party holdings of Eskil Elmér and Marcus Keep pursuant to NASDAQ OMX rules.
About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For media and investor relations questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, info@neurovive.se, www.neurovive.se
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 31 March 2014, at 1:00 p.m. CET.
Tags: